Shenzhen Builds Up R&D Platform For New Combination Drugs
This article was originally published in PharmAsia News
Shenzhen National Biomedical Industry Base recently released its key R&D results at China Hi-Tech Fair. Last March, Shenzhen Ausa Pharmed Co., which has been appointed the new combination drug research center for the biomedical base, received Class I new drug certification from China's State FDA for its enalapril maleate and folic acid tablet. This represents the only new drug with intellectual property rights to obtain such certification in the cardiovascular field in the past three years. Experts observe that innovative drug combination, complemented with expansion of drug indications, may form an effective approach that suits China's situation and helps the nation catch up in the global innovation competition. (Click here for more - Chinese Language)
You may also be interested in...
Hospira’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.
New medicines under evaluation at the European Medicines Agency.
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.